EPCAM and neoplasm: In the work of Keren and colleagues, MIBI-TOF technology was used to resolve regional heterogeneity in the tumour-immune microenvironment by analysing the localisation of 36 proteins, including tumour and immune cell phenotypes, and immuno-regulatory proteins, such as vimentin and EpCAM molecules which are highly expressed in metastatic cancer, in single triple negative breast tumours (Spizzo et al., 2011; Keren et al., 2019; Berr et al., 2023).